ARWR logo

ARWR Cash From Operations

Annual CFO

-$462.85 M
-$308.96 M-200.77%

September 30, 2024


Summary


Performance

ARWR Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherARWRcash flowmetrics:

Quarterly CFO

-$146.27 M
-$9.06 M-6.60%

December 31, 2024


Summary


Performance

ARWR Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherARWRcash flowmetrics:

TTM CFO

-$491.28 M
-$28.43 M-6.14%

December 31, 2024


Summary


Performance

ARWR TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherARWRcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

ARWR Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-200.8%-6.6%-6.1%
3 y3 years-370.2%-6.6%-6.1%
5 y5 years-367.5%-6.6%-6.1%

ARWR Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-370.2%at low-333.2%at low-429.9%at low
5 y5-year-367.5%at low-155.4%at low-366.9%at low
alltimeall time-367.5%at low-155.4%at low-366.9%at low

Arrowhead Pharmaceuticals Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-
-$146.27 M(+6.6%)
-$491.28 M(+6.1%)
Sep 2024
-$462.85 M(+200.8%)
-$137.22 M(+18.9%)
-$462.85 M(+31.7%)
Jun 2024
-
-$115.42 M(+24.9%)
-$351.56 M(+36.8%)
Mar 2024
-
-$92.38 M(-21.6%)
-$256.92 M(+30.9%)
Dec 2023
-
-$117.84 M(+354.5%)
-$196.21 M(+27.5%)
Sep 2023
-$153.89 M(+13.0%)
-$25.93 M(+24.8%)
-$153.89 M(-21.8%)
Jun 2023
-
-$20.78 M(-34.4%)
-$196.70 M(-19.6%)
Mar 2023
-
-$31.67 M(-58.1%)
-$244.74 M(+62.8%)
Dec 2022
-
-$75.52 M(+9.9%)
-$150.34 M(+10.4%)
Sep 2022
-$136.13 M(-179.5%)
-$68.74 M(-0.1%)
-$136.13 M(+48.9%)
Jun 2022
-
-$68.81 M(-209.7%)
-$91.42 M(+75.1%)
Mar 2022
-
$62.73 M(-202.3%)
-$52.22 M(-135.1%)
Dec 2021
-
-$61.31 M(+155.1%)
$148.93 M(-13.1%)
Sep 2021
$171.31 M(-278.8%)
-$24.03 M(-18.8%)
$171.31 M(-6.9%)
Jun 2021
-
-$29.61 M(-111.2%)
$184.08 M(+2.1%)
Mar 2021
-
$263.87 M(-778.0%)
$180.26 M(-262.1%)
Dec 2020
-
-$38.92 M(+245.7%)
-$111.19 M(+16.1%)
Sep 2020
-$95.80 M(-155.4%)
-$11.26 M(-66.3%)
-$95.80 M(+35.4%)
Jun 2020
-
-$33.43 M(+21.2%)
-$70.73 M(+164.1%)
Mar 2020
-
-$27.59 M(+17.2%)
-$26.78 M(+42.6%)
Dec 2019
-
-$23.53 M(-270.4%)
-$18.78 M(-110.9%)
Sep 2019
$173.03 M(-466.4%)
$13.81 M(+31.2%)
$173.04 M(+10.5%)
Jun 2019
-
$10.53 M(-153.7%)
$156.54 M(+18.9%)
Mar 2019
-
-$19.59 M(-111.6%)
$131.61 M(-3.1%)
Dec 2018
-
$168.28 M(-6378.6%)
$135.75 M(-387.5%)
Sep 2018
-$47.22 M(+97.3%)
-$2.68 M(-81.4%)
-$47.22 M(-12.1%)
Jun 2018
-
-$14.41 M(-6.7%)
-$53.75 M(+8.0%)
Mar 2018
-
-$15.44 M(+5.1%)
-$49.75 M(+2.3%)
Dec 2017
-
-$14.69 M(+59.6%)
-$48.63 M(+103.1%)
Sep 2017
-$23.94 M(-62.8%)
-$9.20 M(-11.6%)
-$23.94 M(-3.9%)
Jun 2017
-
-$10.41 M(-27.3%)
-$24.92 M(-24.2%)
Mar 2017
-
-$14.33 M(-243.3%)
-$32.86 M(-1.3%)
Dec 2016
-
$10.00 M(-198.2%)
-$33.28 M(-48.3%)
Sep 2016
-$64.43 M(-1.9%)
-$10.18 M(-44.5%)
-$64.43 M(-2.8%)
Jun 2016
-
-$18.35 M(+24.4%)
-$66.27 M(+8.6%)
Mar 2016
-
-$14.75 M(-30.3%)
-$61.03 M(-2.6%)
Dec 2015
-
-$21.15 M(+75.9%)
-$62.66 M(-4.6%)
Sep 2015
-$65.71 M(+85.5%)
-$12.02 M(-8.4%)
-$65.71 M(+1.7%)
Jun 2015
-
-$13.12 M(-19.9%)
-$64.61 M(+5.5%)
Mar 2015
-
-$16.37 M(-32.4%)
-$61.27 M(+16.5%)
Dec 2014
-
-$24.20 M(+121.6%)
-$52.59 M(+48.5%)
Sep 2014
-$35.42 M(+86.1%)
-$10.92 M(+11.7%)
-$35.42 M(+18.5%)
Jun 2014
-
-$9.78 M(+27.0%)
-$29.89 M(+17.5%)
Mar 2014
-
-$7.70 M(+9.6%)
-$25.45 M(+14.5%)
Dec 2013
-
-$7.02 M(+30.2%)
-$22.22 M(+16.7%)
Sep 2013
-$19.03 M(+24.1%)
-$5.39 M(+1.1%)
-$19.03 M(+4.4%)
Jun 2013
-
-$5.33 M(+19.4%)
-$18.23 M(+8.6%)
Mar 2013
-
-$4.47 M(+16.4%)
-$16.78 M(+1.9%)
Dec 2012
-
-$3.84 M(-16.4%)
-$16.47 M(+7.4%)
Sep 2012
-$15.34 M
-$4.59 M(+18.0%)
-$15.34 M(+23.6%)
Jun 2012
-
-$3.89 M(-6.5%)
-$12.42 M(+30.0%)
Mar 2012
-
-$4.16 M(+53.7%)
-$9.55 M(+43.1%)
DateAnnualQuarterlyTTM
Dec 2011
-
-$2.71 M(+62.7%)
-$6.67 M(+23.8%)
Sep 2011
-$5.39 M(-30.0%)
-$1.66 M(+62.4%)
-$5.39 M(-13.6%)
Jun 2011
-
-$1.02 M(-20.0%)
-$6.24 M(-10.8%)
Mar 2011
-
-$1.28 M(-10.1%)
-$6.99 M(-6.6%)
Dec 2010
-
-$1.42 M(-43.3%)
-$7.49 M(-2.7%)
Sep 2010
-$7.70 M(-49.6%)
-$2.51 M(+41.3%)
-$7.70 M(+1.3%)
Jun 2010
-
-$1.78 M(+0.2%)
-$7.60 M(+4.0%)
Mar 2010
-
-$1.77 M(+8.6%)
-$7.31 M(-28.4%)
Dec 2009
-
-$1.63 M(-32.4%)
-$10.21 M(-33.2%)
Sep 2009
-$15.28 M(-44.6%)
-$2.42 M(+62.8%)
-$15.28 M(-28.1%)
Jun 2009
-
-$1.48 M(-68.3%)
-$21.25 M(-22.5%)
Mar 2009
-
-$4.68 M(-30.1%)
-$27.42 M(-3.6%)
Dec 2008
-
-$6.70 M(-20.1%)
-$28.45 M(+3.1%)
Sep 2008
-$27.58 M(+15.6%)
-$8.38 M(+9.5%)
-$27.58 M(+7.3%)
Jun 2008
-
-$7.65 M(+34.0%)
-$25.70 M(+8.5%)
Mar 2008
-
-$5.71 M(-2.0%)
-$23.68 M(-3.8%)
Dec 2007
-
-$5.83 M(-10.2%)
-$24.61 M(+3.1%)
Sep 2007
-$23.87 M(+61.4%)
-$6.50 M(+15.3%)
-$23.87 M(+13.5%)
Jun 2007
-
-$5.64 M(-15.1%)
-$21.03 M(+5.7%)
Mar 2007
-
-$6.64 M(+30.5%)
-$19.90 M(+19.2%)
Dec 2006
-
-$5.09 M(+38.9%)
-$16.69 M(+12.9%)
Sep 2006
-$14.79 M(+62.6%)
-$3.66 M(-18.7%)
-$14.79 M(+7.9%)
Jun 2006
-
-$4.51 M(+31.3%)
-$13.71 M(+13.0%)
Mar 2006
-
-$3.43 M(+7.6%)
-$12.14 M(+17.4%)
Dec 2005
-
-$3.19 M(+23.3%)
-$10.34 M(+13.7%)
Sep 2005
-$9.10 M(+293.2%)
-$2.59 M(-11.9%)
-$9.10 M(+26.1%)
Jun 2005
-
-$2.93 M(+79.6%)
-$7.21 M(+41.6%)
Mar 2005
-
-$1.63 M(-16.1%)
-$5.09 M(+29.3%)
Dec 2004
-
-$1.95 M(+178.0%)
-$3.94 M(+70.2%)
Sep 2004
-$2.31 M(+1368.5%)
-$700.00 K(-14.2%)
-$2.31 M(+35.3%)
Jun 2004
-
-$815.40 K(+70.3%)
-$1.71 M(+89.5%)
Mar 2004
-
-$478.80 K(+49.5%)
-$902.80 K(+95.5%)
Dec 2003
-
-$320.20 K(+232.5%)
-$461.90 K(+193.1%)
Sep 2003
-$157.60 K(+49.0%)
-$96.30 K(+1184.0%)
-$157.60 K(+109.0%)
Jun 2003
-
-$7500.00(-80.2%)
-$75.40 K(-35.5%)
Mar 2003
-
-$37.90 K(+138.4%)
-$116.90 K(+23.2%)
Dec 2002
-
-$15.90 K(+12.8%)
-$94.90 K(-10.4%)
Sep 2002
-$105.80 K(+29.3%)
-$14.10 K(-71.2%)
-$105.90 K(-0.6%)
Jun 2002
-
-$49.00 K(+208.2%)
-$106.50 K(+46.1%)
Mar 2002
-
-$15.90 K(-40.9%)
-$72.90 K(-18.9%)
Dec 2001
-
-$26.90 K(+83.0%)
-$89.90 K(+9.8%)
Sep 2001
-$81.80 K(+2.1%)
-$14.70 K(-4.5%)
-$81.90 K(-7.2%)
Jun 2001
-
-$15.40 K(-53.2%)
-$88.30 K(-34.3%)
Mar 2001
-
-$32.90 K(+74.1%)
-$134.30 K(+33.9%)
Dec 2000
-
-$18.90 K(-10.4%)
-$100.30 K(+25.1%)
Sep 2000
-$80.10 K(+127.6%)
-$21.10 K(-65.6%)
-$80.20 K(+35.7%)
Jun 2000
-
-$61.40 K(-5681.8%)
-$59.10 K(-2669.6%)
Mar 2000
-
$1100.00(-8.3%)
$2300.00(+91.7%)
Dec 1999
-
$1200.00
$1200.00
Sep 1999
-$35.20 K(<-9900.0%)
-
-
Sep 1998
$100.00(-97.8%)
-
-
Sep 1997
$4600.00
-
-

FAQ

  • What is Arrowhead Pharmaceuticals annual cash flow from operations?
  • What is the all time high annual CFO for Arrowhead Pharmaceuticals?
  • What is Arrowhead Pharmaceuticals annual CFO year-on-year change?
  • What is Arrowhead Pharmaceuticals quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Arrowhead Pharmaceuticals?
  • What is Arrowhead Pharmaceuticals quarterly CFO year-on-year change?
  • What is Arrowhead Pharmaceuticals TTM cash flow from operations?
  • What is the all time high TTM CFO for Arrowhead Pharmaceuticals?
  • What is Arrowhead Pharmaceuticals TTM CFO year-on-year change?

What is Arrowhead Pharmaceuticals annual cash flow from operations?

The current annual CFO of ARWR is -$462.85 M

What is the all time high annual CFO for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals all-time high annual cash flow from operations is $173.03 M

What is Arrowhead Pharmaceuticals annual CFO year-on-year change?

Over the past year, ARWR annual cash flow from operations has changed by -$308.96 M (-200.77%)

What is Arrowhead Pharmaceuticals quarterly cash flow from operations?

The current quarterly CFO of ARWR is -$146.27 M

What is the all time high quarterly CFO for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals all-time high quarterly cash flow from operations is $263.87 M

What is Arrowhead Pharmaceuticals quarterly CFO year-on-year change?

Over the past year, ARWR quarterly cash flow from operations has changed by -$9.06 M (-6.60%)

What is Arrowhead Pharmaceuticals TTM cash flow from operations?

The current TTM CFO of ARWR is -$491.28 M

What is the all time high TTM CFO for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals all-time high TTM cash flow from operations is $184.08 M

What is Arrowhead Pharmaceuticals TTM CFO year-on-year change?

Over the past year, ARWR TTM cash flow from operations has changed by -$28.43 M (-6.14%)